Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 528 participants.
Also called NCT02791958
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 528 participants
- Sponsor
- Registry
-
NCT02791958
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Unknown status
Technical summary
Registry record NCT02791958. Randomized; no masking; primary purpose treatment. Start 2016-03 (registry gives no type); primary completion 2017-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy
- Condition
- Hypertension
- Intervention (Drug)
- Cardiovascular Fixed Dose Combination Pill AAR
- Intervention (Drug)
- Atorvastatin 40 mg
- Intervention (Drug)
- Ramipril 10 mg
- Lead sponsor
- Ferrer Internacional S.A.
Record details
- Record id
cardio:ct-nct02791958- Content hash
e11b783ae09cc8c110879eabd530851d4fc7783ff388d691c99a1c42d2e9f668